Kevin Pan

Kevin Pan began their career in 1996 as a Research Scientist at Johnson & Johnson. In 2001, they joined Hutchison MediPharma as Group Director of Business Development and Director and Senior Director of Drug Discovery Chemistry. In 2007, they founded BroadSources, Inc. and served as its President. In 2010, they founded Asieris Pharmaceuticals, where they are currently President and CEO. Asieris is a private, VC-backed, clinical-stage biotech company focusing on discovery and development of small molecular anti-cancer drugs. APL-1202 is the company's leading candidate currently in a phase III trial in China for the treatment of non-muscle invasive bladder cancer (NMIBC).

Kevin Pan obtained their Bachelor's degree in Chemistry from Fudan University in 1990 and their Doctor of Philosophy - PhD in Bioorganic Chemistry from Rutgers University in 2000.